Under New Management

Marc and team's incompetence is a serious detriment to SP. Missteps on cash raises and dilution. Unable to generate outside revenue taking money from long term holders. Send them packing vote them out. Saying that we have a case to help people and male big money.

What the FDA Cares About

The FDA evaluates drugs on three main axes:

Efficacy (clear benefit)

Safety (especially compared to alternatives)

Unmet need (especially for hard-to-treat populations)

➡️ Efti hits all three:

one of the safest + most effective IO combinations in development right now. If upcoming data stay consistent, it will be very hard for the FDA to say no, especially for patient groups with few options

Works better than pembrolizumab alone in PD-L1–low/negative NSCLC and HNSCC patients

Far safer than most dual checkpoint regimens